 in January based on early results suggesting Leqembi worked by clearing a sticky brain plaque linked to the disease. Following the 1,800-patient study, which found the drug slowed memory and thinking decline by about five months, it has now got the green light - mounting pressure on Britain to follow suit. Hilary Evans, chief executive at Alzheimer's Research UK, said: "This welcome news from the US signals a step towards a world where Alzheimer's disease is treatable, but should also serve as a wake-up call. "Today's ruling involved careful review of data from a rigorous study of 1,800 patients. "A similar process is currently underway in the UK, led by the Medicines and Healthcare products Regulatory Agency (MHRA). "We've written to the MHRA urging them to complete this review as a matter of urgency, without compromising on quality, so people with Alzheimer's in the UK aren't left in limbo. "We believe that a rapid regulatory decision on lecanemab will further strengthen the UK's international reputation as a leader in dementia, attract even greater commercial investment in UK clinical trials, and ultimately benefit the one in two of us who will either develop dementia in the future, or care for someone who has it. "With a UK decision on the horizon, today's news underlines the urgency of getting the NHS ready for new medicines like lecanemab." FDA's neurology dru){kind=link}
A NEW drug which can slow the progression of Alzheimer’s has been approved for use in the US.
Lecanemab, known commercially as Leqembi, will be available for patients with mild dementia and other symptoms that appear in the early stages of the brain-robbing disease.
It is the first medicine that has shown to modestly slow cognitive decline.
Japanese drugmaker Eisai received conditional approval from the Food and Drug Administration (FDA) in January based on early results suggesting Leqembi worked by clearing a sticky brain plaque linked to the disease.
Following the 1,800-patient study, which found the drug slowed memory and thinking decline by about five months, it has now got the green light – mounting pressure on Britain to follow suit.